Clinical Trial Update: Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT) [Phase 1, Phase 2]

View source ↗

Summary

Open-label extension study evaluating long-term safety of DRX008A (ERT) in patients with Type 1 Gaucher disease completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• DRX008A (DRX008A)

Snippet

Sponsor: Shire | Conditions: Gaucher Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-06-23